89Zr-GSK2849330

**89Zr-GSK2849330 is a radiolabeled monoclonal antibody used for immuno-PET imaging.** It consists of the anti-HER3 monoclonal antibody GSK2849330 conjugated with the radioisotope zirconium-89 (89Zr). The parent antibody, GSK2849330, targets human epidermal growth factor receptor 3 (HER3/ERBB3), blocking HER3/Neuregulin 1 (NRG1) signaling in cancer cells and is engineered for enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity[4][7]. The radiolabeled form enables noninvasive PET imaging to assess biodistribution, tumor targeting, and target engagement in patients with HER3-positive tumors[1][2][5]. This approach supports dose selection and evaluation of pharmacodynamics in early-phase clinical trials. The drug has been studied primarily as a diagnostic tool to visualize tissue drug disposition and measure target engagement at the site of action in oncology settings[1][2].

Other names

89Zr-labeled GSK2849330Zirconium-89 labeled GSK2849330Zirconium89 labeled GSK2849330Zirconium 89 labeled GSK2849330